Dallas, TX: ReportsandReports announce it will carry Eisai Co. Ltd: PharmaVitae Profile Market Research Report in its Store.
Browse complete Eisai Co. Ltd: PharmaVitae Profile Report
Introduction
This analysis examines the historical and forecast performance for Eisai in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
- Benchmark Eisai’s performance against key rivals in the prescription pharmaceutical sector
- See how the loss of patent protection on Eisai’s blockbuster products Aricept and AcipHex/Pariet will impact Rx revenue performance over 200713
- Evaluate Eisai’s long-term growth potential following the acquisition of US companies Morphotek and MGI Pharma in 2007 and 2008 respectively
Table Of Contents
CHAPTER 1 ABOUT THIS PROFILE 2
Executive summary 2
Quarterly news update 2
Company introduction 2
Company sales 2
Company financials 2
Key products and competitors 3
Data sourcing 3
Sales data 3
Analyst consensus 3
CHAPTER 2 EXECUTIVE SUMMARY 4
Key findings 4
Prescription pharmaceutical sales performance, 2001-13 5
Financial performance, 2001-13 6
Eisai: PharmaVitae forecasts at a glance 7
Strategic insight 8
1) 2001-07: Impressive Rx revenue growth 8
2) 2007-10: M&A sustains Rx revenue 9
3) 2010-13: Life after Aricept and AcipHex? 10
Aricept and AcipHex/Pariet face generic competition over 2010-13 10
Launch portfolio unable to offset expiry declines 10
Further M&A on the horizon? 11
Operating margin remains robust despite revenue decline 11
SWOT analysis 12
Strengths 12
Weaknesses 13
Opportunities 13
Threats 15
CHAPTER 3 QUARTERLY NEWS UPDATE 20
Product developments 20
Deals and alliances 21
Product deals 21
Technology deals 22
M&A activity 23
Company announcements 23
Future product milestones 24
CHAPTER 4 COMPANY INTRODUCTION 25
Key findings 25
Background 26
Key corporate developments 26
M&A history 27
Merger of Sakuragaoka Research Laboratory and Nihon Eisai 27
Acquisition of Morphotek 27
Acquisition of Sanko Junyaku 27
Acquisition of MGI Pharma 28
Current corporate structure 29
Pharmaceuticals business unit structure 30
Pharmaceuticals business unit structure 30
Prescription pharmaceuticals (Rx) 30
Diagnostics 31
Consumer healthcare 31
CHAPTER 5 COMPANY SALES 32
Key findings 32
Prescription pharmaceutical sales and growth rate analysis, 2001-13 33
Product analysis 35
Product analysis, 2001-07 35
Product analysis, 2007-13 39
Therapy area analysis 43
Therapy area analysis, 2001-07 44
Therapy area analysis, 2007-13 46
Therapy area focus, 2001-13 48
Geographic analysis 49
Geographic analysis, 2001-07 50
Geographic analysis, 2007-13 51
Geographic focus, 2001-13 55
Launch/core/expiry analysis 56
Explanation of launch/core/expiry analysis 56
Launch analysis, 2007-13 57
Core analysis, 2007-13 59
Expiry analysis, 2007-13 60
Launch/core/expiry configuration, 2007-13 62
Molecule type analysis 63
Molecule type analysis, 2001-07 64
Molecule type analysis, 2007-13 65
Externalization analysis 67
Externalization analysis, 2001-07 68
Externalization analysis, 2007-13 70
CHAPTER 6 COMPANY FINANCIALS 73
Key findings 73
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07 74
Financial statements, 2001-07 76
Profit and loss account, 2001-07 76
Balance sheet, 2001-07 78
Operating costs and profit analysis 80
Operating costs and profit analysis, 2001-07 81
Operating cost ratio and profit margin analysis, 2001-07 83
Operating cost ratio and profit margin analysis, 2007-13 84
Operating costs and profit analysis, 2007-13 86
Return on capital employed analysis 88
Capital employed analysis, 2001-07 89
Return on capital employed analysis, 2001-07 91
Market capitalization analysis 93
Market capitalization analysis, 2001-07 93
Total shareholder returns analysis, 2001-07 94
CHAPTER 7 KEY PRODUCTS AND COMPETITORS 95
Key findings 95
Overview 96
Central nervous system 97
Aricept 97
Overview 97
Sales forecast 98
Methycobal 100
Overview 100
Sales forecast 101
Lusedra 102
Overview 102
Sales forecast 103
Inovelon/Banzel 104
Overview 104
Sales forecast 105
Gastroenterology 107
AcipHex/Pariet 107
Overview 107
Sales forecast 108
Selbex 111
Overview 111
Sales forecast 112
Oncology 113
Aloxi 113
Overview 113
Sales forecast 114
Dacogen 116
Overview 116
Sales forecast 117
E7389 120
Overview 120
Sales forecast 121
Gliadel 123
Overview 123
Sales forecast 124
Infectious disease 125
E5564 125
Overview 125
Sales forecast 126
Immunology and inflammation 128
Humira 128
Overview 128
Sales forecast 129
CHAPTER 8 APPENDIX 130
R&D pipeline 130
Indication broadening pipeline 131
References 132
Abbreviations 133
Exchange rates 134
Browse complete Eisai Co. Ltd: PharmaVitae Profile Report
Browse all Healthcare Market Research Reports
Browse all Datamonitor Market Research Reports RSS
Browse all Latest Report
Related Reports:
Takeda Pharmaceutical Co. Ltd: PharmaVitae Profile
Daiichi Sankyo Co., Ltd: PharmaVitae Profile
Bristol-Myers Squibb Co.: PharmaVitae Profile
About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
